These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16077084)

  • 21. siRNAs in drug discovery: target validation and beyond.
    Natt F
    Curr Opin Mol Ther; 2007 Jun; 9(3):242-7. PubMed ID: 17608022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNAi therapy for neurodegenerative diseases.
    Boudreau RL; Davidson BL
    Curr Top Dev Biol; 2006; 75():73-92. PubMed ID: 16984810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissecting cancer pathways and vulnerabilities with RNAi.
    Westbrook TF; Stegmeier F; Elledge SJ
    Cold Spring Harb Symp Quant Biol; 2005; 70():435-44. PubMed ID: 16869781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic approaches to drug discovery.
    Ricke DO; Wang S; Cai R; Cohen D
    Curr Opin Chem Biol; 2006 Aug; 10(4):303-8. PubMed ID: 16822705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Modern genetic approaches to the search for targets for medicinal preparations].
    Sarantseva SV; Shvartsman AL
    Genetika; 2009 Jul; 45(7):869-80. PubMed ID: 19705737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of therapeutic drug targets through genetically manipulated mice: are we getting it right?
    Matthaei KI
    Pharmacol Ther; 2009 Jul; 123(1):32-6. PubMed ID: 19375454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of target validation in drug discovery and development.
    Lowe JA; Jones P; Wilson DM
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):581-4. PubMed ID: 19736617
    [No Abstract]   [Full Text] [Related]  

  • 28. Embracing complexity, inching closer to reality.
    Schadt EE; Sachs A; Friend S
    Sci STKE; 2005 Aug; 2005(295):pe40. PubMed ID: 16077086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
    Singh M; Johnson L
    Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of molecular biology on drug discovery.
    Belfield GP; Delaney SJ
    Biochem Soc Trans; 2006 Apr; 34(Pt 2):313-6. PubMed ID: 16545102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice.
    De Souza AT; Dai X; Spencer AG; Reppen T; Menzie A; Roesch PL; He Y; Caguyong MJ; Bloomer S; Herweijer H; Wolff JA; Hagstrom JE; Lewis DL; Linsley PS; Ulrich RG
    Nucleic Acids Res; 2006; 34(16):4486-94. PubMed ID: 16945951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
    Showalter HD; Denny WA
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated expressional analysis: application to the drug discovery process.
    Ilyin SE; Horowitz D; Belkowski SM; Xin H; Eckardt AJ; Darrow AL; Chen C; Maley D; D'Andrea M; Plata-Salamán CR; Derian CK
    Methods; 2005 Nov; 37(3):280-8. PubMed ID: 16308157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA interference as a novel and powerful tool in immunopharmacological research.
    Kong Y; Ruan L; Ma L; Cui Y; Wang JM; Le Y
    Int Immunopharmacol; 2007 Apr; 7(4):417-26. PubMed ID: 17321464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biology calls the targets: combining RNAi and disease biology.
    van Es HH; Arts GJ
    Drug Discov Today; 2005 Oct; 10(20):1385-91. PubMed ID: 16253877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.
    Flynn MA; McNeil DA; Maloff B; Mutasingwa D; Wu M; Ford C; Tough SC
    Obes Rev; 2006 Feb; 7 Suppl 1():7-66. PubMed ID: 16371076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes.
    Hofstadler SA; Sannes-Lowery KA
    Nat Rev Drug Discov; 2006 Jul; 5(7):585-95. PubMed ID: 16816839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospects of RNA interference therapy for cancer.
    Pai SI; Lin YY; Macaes B; Meneshian A; Hung CF; Wu TC
    Gene Ther; 2006 Mar; 13(6):464-77. PubMed ID: 16341059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.